Company: BIAF
Filing Date: 2025-05-02
Form Type: S-1
Source: 0001641172-25-008170
Chunk: 172

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-02
Form: S-1
Chunk 172
---
arrant (the last reported sale price of our Common Stock on Nasdaq on April 25, 2025). We are also offering Pre-Funded Warrants to those purchasers whose purchase of shares of our Common Stock in this offering would result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding shares of Common Stock following the consummation of this offering in lieu of the shares of Common Stock that would result in such excess ownership. For each Pre-Funded Warrant sold, the number of shares of Common Stock sold will be reduced on a one-for-one basis. Each share of our Common Stock or Pre-Funded Warrant is being sold together with one April 2025 Warrant to purchase one and one-half share of Common Stock. The shares of Common Stock and/or Pre-Funded Warrants and the accompanying April 2025 Warrants can only be purchased together in this offering but will be issued separately and will be immediately separable upon issuance. We are also registering the shares of our Common Stock issuable from time to time upon exercise of the Pre-Funded Warrants, April 2025 Warrants and Placement Agent Warrants offered hereby.

Common Stock

The description of our Common Stock under the section “Description of Our Securities—Common Stock” in this prospectus is incorporated herein by reference.

April 2025 Warrants

The following summary of certain terms and provisions of the April 2025 Warrants included with the shares of Common Stock and the Pre-Funded Warrants that are being issued hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the Warrant Agent Agreement between us and VStock Transfer, LLC, as Warrant Agent, and the form of the April 2025 Warrants, both of which will be filed as exhibits to the registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the Warrant Agent Agreement, including the annexes thereto, and the form of April 2025 Warrant for a complete description of the terms and conditions of the April 2025 Warrants.

Warrant Stockholder Approval

The April 2025 Warrants are not exercisable without stockholder approval. Beginning on the later of the effective date of the filing of an amendment to our certificate of incorporation with the Secretary of State of the State of Delaware to increase our authorized